Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocarcinoma.
Adenocarcinoma
/ drug therapy
Animals
Carcinoma, Pancreatic Ductal
/ drug therapy
Cell Line, Tumor
Decitabine
/ pharmacology
Drug Repositioning
/ methods
Humans
Mice
Mice, Inbred NOD
Mice, SCID
Mutation
/ drug effects
Pancreatic Neoplasms
/ drug therapy
Protein Kinase Inhibitors
/ pharmacology
Proto-Oncogene Proteins p21(ras)
/ metabolism
Pyrimidines
/ pharmacology
Signal Transduction
/ drug effects
Journal
Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R
Informations de publication
Date de publication:
01 Nov 2019
01 Nov 2019
Historique:
received:
17
01
2019
revised:
24
07
2019
accepted:
29
08
2019
pubmed:
8
9
2019
medline:
29
5
2020
entrez:
8
9
2019
Statut:
ppublish
Résumé
Mutated KRAS protein is a pivotal tumor driver in pancreatic cancer. However, despite comprehensive efforts, effective therapeutics that can target oncogenic KRAS are still under investigation or awaiting clinical approval. Using a specific KRAS-dependent gene signature, we implemented a computer-assisted inspection of a drug-gene network to
Identifiants
pubmed: 31492820
pii: 0008-5472.CAN-19-0187
doi: 10.1158/0008-5472.CAN-19-0187
doi:
Substances chimiques
KRAS protein, human
0
Protein Kinase Inhibitors
0
Pyrimidines
0
Decitabine
776B62CQ27
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
pyrimidine
K8CXK5Q32L
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5612-5625Informations de copyright
©2019 American Association for Cancer Research.